Skip to main content

GH Guardant Health, Inc.

Healthcare

170.73 -8.07 -4.51% Close 11/2
Since 2024-12-02 +403.4%
Open
179.50
High
180.04
Low
167.94
Prev close
178.80
Volume
2.4M
Amplitude
6.77%
Revenue YoY (TTM)
+42.7%
52W 74.55 191.05

Is Guardant Health, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Growth: Good, Momentum: Strong, Risk / liquidity: Good.

Valuation Neutral Free-cash-flow yield is Average.
TTM P/E -51.23 N/A
Price / book -107.66 N/A
Free-cash-flow yield (%) -0.95 41th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral ROE, TTM is Top, but Operating margin, TTM is Lagging.
ROE, TTM (%) 203.46 97th percentile Top
Operating margin, TTM (%) -39.75 19th percentile Lagging
FCF margin, TTM (%) -19.31 24th percentile Average
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top; Diluted EPS growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 42.74 86th percentile Top
Diluted EPS growth, TTM YoY (%) 4.18 57th percentile Good
Momentum Strong All 2 indicators are Top.
60-day return (%) 13.47 88th percentile Top
240-day return (%) 89.47 95th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 300,218,869 95th percentile Top
60-day annualized volatility (%) 45.52 51th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Guardant Health, Inc. (GH) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Guardant Health, Inc. to every stock like it

AI finds several complementary traits of Guardant Health, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Guardant Health, Inc.

Guardant Health, Inc. (GH) peers and tracking

Watchlist

This page refreshes daily after the close. Add Guardant Health, Inc. to your watchlist to track signal changes on your next visit.

Guardant Health, Inc. (GH) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 98.22%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
24 historical occurrences (since 2019-04-08)

Average forward return after Top-quintile 6-month momentum

20-day: Win 62.5%, Sample 24, Median +5.13%, Excess +0.32%, Beat mkt rate 62.5%

60-day: Win 58.3%, Sample 24, Median +10.8%, Excess +5.52%, Beat mkt rate 45.8%

120-day: Win 54.5%, Sample 22, Median +4.5%, Excess +0.22%, Beat mkt rate 40.9%

120 days after: historical avg +11.4%

20-day +2.16%
60-day +10.91%
120-day +11.4%
20-day
60-day
120-day
Win
62.5%
58.3%
54.5%
Sample
24
24
22
Median
+5.13%
+10.8%
+4.5%
Excess
+0.32%
+5.52%
+0.22%
Beat mkt rate
62.5%
45.8%
40.9%

Over 22 occurrences, 120-day forward avg gained 11.4%, beat the market by 0.22 pts; win rate 54.5%.

Filed revenue acceleration

Active · now 42.74%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

18 historical occurrences (since 2019-05-10)

Average forward return after Filed revenue acceleration

20-day: Win 55.6%, Sample 18, Median +10.29%, Excess +6.01%, Beat mkt rate 61.1%

60-day: Win 55.6%, Sample 18, Median +6.1%, Excess +8.35%, Beat mkt rate 55.6%

120-day: Win 58.8%, Sample 17, Median +14.45%, Excess +17.11%, Beat mkt rate 64.7%

120 days after: historical avg +20.52%

20-day +7.03%
60-day +10.63%
120-day +20.52%
20-day
60-day
120-day
Win
55.6%
55.6%
58.8%
Sample
18
18
17
Median
+10.29%
+6.1%
+14.45%
Excess
+6.01%
+8.35%
+17.11%
Beat mkt rate
61.1%
55.6%
64.7%

Over 17 occurrences, 120-day forward avg gained 20.52%, beat the market by 17.11 pts; win rate 58.8%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

13 times historically; 60-day forward avg +26.57%, win rate 91.7%, beating the market by +23.71 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

17 times historically; 60-day forward avg +10.84%, win rate 52.9%, beating the market by +7.7 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.